Aurinia Pharmaceuticals (AUPH) has drawn fresh attention after reporting first quarter 2026 results. Revenue was US$77.71 million and net income was US$34.36 million, both higher than the prior year period.

The earnings beat and reiterated 2026 guidance arrived alongside a 4.9% 90 day share price return and an 86.7% 1 year total shareholder return, suggesting strong recent momentum despite short term share price weakness.

If Aurinia’s results have you rethinking healthcare exposure, it could be a good moment to broaden your watchlist with 35 healthcare AI stocks

With the stock up 86.7% over the past year and trading at a discount to the US$17 analyst target, the key question now is whether Aurinia is undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 10.9% Undervalued

Aurinia’s most followed narrative places fair value at $17, compared with a last close of $15.14, framing the current price as below that reference point.

Operational efficiency improvements, including a strategic 2024 restructuring and focus on cost management, have driven gross margin expansion (from mid 80s to near 90%) and significant increases in operating leverage, which are likely to enhance net margins even as R&D spending increases. (Net margins)

Curious what kind of revenue trajectory and profit margins anchor that $17 fair value? The narrative leans on ambitious growth, resilient profitability, and a richer future earnings multiple.

Result: Fair Value of $17 (UNDERVALUED)

However, the story can change quickly if LUPKYNIS faces tougher competition or pricing pressure, or if higher R&D spending weighs more heavily on future profitability.

Next Steps

With sentiment split between potential upside and clear risks, it is worth looking at the underlying data yourself and forming an independent view. To weigh both sides of the story quickly, start with these 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Aurinia has sharpened your interest, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could fit your goals.

• Target potential upside by focusing on companies that combine quality with attractive pricing through the 51 high quality undervalued stocks.
• Prioritise resilience and sleep a little easier at night by hunting for companies in the 71 resilient stocks with low risk scores.
• Uncover lesser known opportunities with solid fundamentals before others notice them using the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.